

**Clinical trial results:****A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Riloncept for the Prophylaxis of Gout Flares in Patients on Urate-Lowering Therapy.****Summary**

EudraCT number	2008-007784-16
Trial protocol	DE
Global end of trial date	14 January 2011

Results information

Result version number	v1
This version publication date	31 March 2017
First version publication date	31 March 2017

Trial information**Trial identification**

Sponsor protocol code	IL1T-GA-0815
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00856206
WHO universal trial number (UTN)	-
Other trial identifiers	Study Name: RE-SURGE

Notes:

Sponsors

Sponsor organisation name	Regeneron Pharmaceuticals, Inc.
Sponsor organisation address	777 Old Saw Mill River Rd., Tarrytown, United States, 10591
Public contact	Clinical Trials information, Regeneron Pharmaceuticals, Inc., clinicaltrials@regeneron.com
Scientific contact	Clinical Trials information, Regeneron Pharmaceuticals, Inc., clinicaltrials@regeneron.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 February 2011
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 January 2011
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to assess the safety and tolerability of 160 mg of subcutaneous (SC) therapy with Riloncept in the prophylaxis of gout flares in subjects on uric acid-lowering therapy.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Conference on Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 March 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 14
Country: Number of subjects enrolled	India: 22
Country: Number of subjects enrolled	Indonesia: 14
Country: Number of subjects enrolled	South Africa: 570
Country: Number of subjects enrolled	Taiwan: 11
Country: Number of subjects enrolled	United States: 684
Worldwide total number of subjects	1315
EEA total number of subjects	14

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	1110
From 65 to 84 years	205
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 71 study sites in United States and rest of world (ROW) between 23 March 2009 to 14 January 2011. A total of 2311 subjects were screened in the study.

Pre-assignment

Screening details:

Out of 2311 subjects, 1315 were randomized and treated in the study. Subjects were randomized in 3:1 ratio to receive Rilonacept 160 mg or placebo.

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection in left and right upper arm, the left and right abdomen, and the left and right thigh.

Arm title	Rilonacept 160 mg
------------------	-------------------

Arm description:

Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

Arm type	Experimental
Investigational medicinal product name	Rilonacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection in left and right upper arm, the left and right abdomen, and the left and right thigh.

Number of subjects in period 1	Placebo	Rilonacept 160 mg
Started	330	985
Completed	276	824
Not completed	54	161
Other than specified above	3	10
Consent withdrawn by subject	15	36
Death	2	2
Adverse event	10	46
Decision by the Sponsor	4	8
Lost to follow-up	13	39
Lack of efficacy	1	2
Protocol deviation	6	18

Baseline characteristics

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Two subcutaneous injections of Placebo (for Rilonecept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.

Reporting group title	Rilonecept 160 mg
-----------------------	-------------------

Reporting group description:

Two subcutaneous injections of Rilonecept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonecept qw from Week 1 to Week 15.

Reporting group values	Placebo	Rilonecept 160 mg	Total
Number of subjects	330	985	1315
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	52.4 ± 10.55	52.8 ± 11.48	-
Gender categorical Units: Subjects			
Female	33	128	161
Male	297	857	1154
Ethnicity Units: Subjects			
Hispanic or Latino	11	38	49
Not Hispanic or Latino	319	947	1266
Unknown or Not Reported	0	0	0
Race Units: Subjects			
American Indian or Alaska Native	2	7	9
Asian	47	115	162
Native Hawaiian or Other Pacific Islander	1	3	4
Black or African American	70	202	272
White	210	658	868
More than one race	0	0	0
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Two subcutaneous injections of Placebo (for Rilonecept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.	
Reporting group title	Rilonecept 160 mg
Reporting group description:	
Two subcutaneous injections of Rilonecept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonecept qw from Week 1 to Week 15.	

Primary: Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs)

End point title	Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) ^[1]
End point description:	
Any untoward medical occurrence in a subject who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the administration of first dose of study drug up to 35 days after the last dose of study drug). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included subjects with both serious and non-serious AEs. Safety analysis set that included all subjects who received any study drug and safety analyses were based on the treatment received.	
End point type	Primary
End point timeframe:	
Baseline up to Week 20	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.	

End point values	Placebo	Rilonecept 160 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	330	935		
Units: percentage of participants				
number (not applicable)				
With at least 1 TEAE	59.1	66.6		
With TEAEs related to study drug	13	27.5		
With serious TEAEs	3.9	3.1		
With TEAEs resulting in drug Withdrawal	3.3	5		
With serious TEAEs resulting in drug withdrawal	1.8	1.1		
With TEAEs leading to study discontinuation	3	4.7		
With serious TEAE leading to study discontinuation	1.5	1		
Treatment emergent deaths	0.3	0.2		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Gout Flares Per Subject Assessed From Day 1 to Day 112 (Week 16)

End point title	Number of Gout Flares Per Subject Assessed From Day 1 to Day 112 (Week 16)
-----------------	--

End point description:

A gout flare was defined as subject reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per subject was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. Full analysis set (FAS) that included all randomized subjects who received any study medication, and was based on the treatment allocated by the Interactive voice response system (IVRS) at randomization (as randomized). Here, number of subjects analyzed=subjects with available data for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 to Day 112 (Week 16)

End point values	Placebo	Rilonacept 160 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	323	952		
Units: Gout flares				
arithmetic mean (standard deviation)	1.73 (\pm 2.69)	0.51 (\pm 1.17)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With at Least One Flare From Day 1 to Day 112 (Week 16)

End point title	Percentage of Subjects With at Least One Flare From Day 1 to Day 112 (Week 16)
-----------------	--

End point description:

A gout flare was defined as subject reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of subjects with at least one gout flare was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment

period or not. FAS that included all randomized subjects who received any study medication, and was based on the treatment allocated by the IVRS at randomization (as randomized).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 to Day 112 (Week 16)

End point values	Placebo	Rilonacept 160 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	330	985		
Units: percentage of subjects				
number (not applicable)	51.1	25.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With at Least Two Flares From Day 1 to Day 112 (Week 16)

End point title	Percentage of Subjects With at Least Two Flares From Day 1 to Day 112 (Week 16)
-----------------	---

End point description:

A gout flare was defined as subject reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of subjects with at least two gout flare was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted regardless whether the flares occurred during the treatment period or not. FAS that included all randomized subjects who received any study medication, and was based on the treatment allocated by the IVRS at randomization (as randomized).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 to Day 112 (Week 16)

End point values	Placebo	Rilonacept 160 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	330	985		
Units: percentage of subjects				
number (not applicable)	51.1	25.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Gout Flare Days Per Subject From Day 1 to Day 112 (Week 16)

End point title	Number of Gout Flare Days Per Subject From Day 1 to Day 112 (Week 16)
-----------------	---

End point description:

A gout flare was defined as subjects reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per subject was reported for this outcome measure. Flare days were counted up to Week 16, regardless of whether or not the flares occurred during the treatment period. FAS that included all randomized participants who received any study medication, and was based on the treatment allocated by the IVRS at randomization (as randomized). Here, number of subjects analyzed=subjects with available data for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 to Day 112 (Week 16)

End point values	Placebo	Riloncept 160 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	323	952		
Units: Gout flare Days				
arithmetic mean (standard deviation)	7.66 (\pm 11.79)	2.66 (\pm 7.69)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (time from the administration of first dose of study drug up to 35 days after the last dose of study drug).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Two subcutaneous injections of Placebo (for Rilonecept) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.

Reporting group title	Rilonecept 160 mg
-----------------------	-------------------

Reporting group description:

Two subcutaneous injections of Rilonecept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonecept qw from Week 1 to Week 15.

Serious adverse events	Placebo	Rilonecept 160 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 330 (3.94%)	31 / 985 (3.15%)	
number of deaths (all causes)	1	2	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal cancer stage unspecified			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			

subjects affected / exposed	0 / 330 (0.00%)	2 / 985 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aneurysm			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding varicose vein			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	1 / 330 (0.30%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Cyst			
subjects affected / exposed	1 / 330 (0.30%)	0 / 985 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	1 / 330 (0.30%)	0 / 985 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Bipolar disorder			
subjects affected / exposed	1 / 330 (0.30%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 330 (0.30%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 330 (0.00%)	2 / 985 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 330 (0.00%)	2 / 985 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 330 (0.30%)	2 / 985 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 330 (0.00%)	2 / 985 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	1 / 330 (0.30%)	0 / 985 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	1 / 330 (0.30%)	0 / 985 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer perforation			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	1 / 330 (0.30%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal impairment			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty tophus			

subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Arthritis bacterial			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	2 / 330 (0.61%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis viral			
subjects affected / exposed	1 / 330 (0.30%)	0 / 985 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	0 / 330 (0.00%)	1 / 985 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	1 / 330 (0.30%)	0 / 985 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	1 / 330 (0.30%)	2 / 985 (0.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Rilonacept 160 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	74 / 330 (22.42%)	266 / 985 (27.01%)	
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	20 / 330 (6.06%)	54 / 985 (5.48%)	
occurrences (all)	21	61	
Nervous system disorders			
Headache			
subjects affected / exposed	26 / 330 (7.88%)	90 / 985 (9.14%)	
occurrences (all)	45	169	
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	1 / 330 (0.30%)	61 / 985 (6.19%)	
occurrences (all)	1	195	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	20 / 330 (6.06%)	65 / 985 (6.60%)	
occurrences (all)	41	85	
Pain in extremity			

subjects affected / exposed	15 / 330 (4.55%)	52 / 985 (5.28%)	
occurrences (all)	21	74	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 November 2009	It included the following changes: -Specified that subjects with a history of inadequate urate-lowering response to allopurinol, or a history of allergic reaction, contraindication, or intolerance to allopurinol, were ineligible for the study (for those subjects treated with allopurinol); -Specified that who had an absolute or relative contraindication to naproxen, oral glucocorticoids (e.g, prednisolone, prednisone), and colchicine were ineligible for the study; and also specified stopping rules for discontinuation of study drug; -Clarified that mandatory immediate termination from the study was required if a subject becomes pregnant during the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported